ReviewSeminars in radiation oncology2010
Enhancing radiotherapy through a greater understanding of homologous recombination.
Review in Seminars in radiation oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Dual-Pronged Hafnia-Prodrug-Lipid Nanoplatform Coupling Radiosensitization and DNA Homologous Recombination Inhibition.ACS nano medicine · 2026Article
- Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery-Does It Matter?Brain sciences · 2025Review
- Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.PLoS medicine · 2021Article
- The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.Scientific reports · 2016Article
- Regulation of recombination and genomic maintenance.Cold Spring Harbor perspectives in biology · 2015Review
- The polyamine catabolic enzyme SAT1 modulates tumorigenesis and radiation response in GBM.Cancer research · 2014Article
- PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.Biochimica et biophysica acta · 2014Review
- Reversion of the ErbB malignant phenotype and the DNA damage response.Experimental and molecular pathology · 2012Review
- A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.Journal of the National Cancer Institute · 2012Article
- Targeting DNA repair and the cell cycle in glioblastoma.Journal of neuro-oncology · 2012Review
- Role of IGF-1 receptor in radiation response.Translational oncology · 2012Article
- Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010.Radiation research · 2011Article
- Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy.Mutation research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Radiotherapy for the treatment of cancer can cause a wide range of cellular effects, the most biologically potent of which is the double-strand break in DNA. The process of repairing DNA double-strand breaks involves 1 of 2 major mechanisms: nonhomologous end joining or homologous recombination. In this review, we review the molecular mechanisms of homologous recombination, in particular as it relates to the repair of DNA damage from ionizing radiation. We also present specific situations in which homologous recombination may be dysfunctional in human cancers and how this functional abnormality can be recognized. We also discuss the therapeutic opportunities that can be exploited based on deficiencies in homologous recombination at various steps in the DNA repair pathway. Side-by-side with these potential therapeutic opportunities, we review the contemporary clinical trials in which strategies to exploit these defects in homologous recombination can be enhanced by the use of radiotherapy in conjunction with biologically targeted agents. We conclude that the field of radiation oncology has only scratched the surface of a potentially highly efficacious therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.